CL2020002087A1 - Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b. - Google Patents
Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b.Info
- Publication number
- CL2020002087A1 CL2020002087A1 CL2020002087A CL2020002087A CL2020002087A1 CL 2020002087 A1 CL2020002087 A1 CL 2020002087A1 CL 2020002087 A CL2020002087 A CL 2020002087A CL 2020002087 A CL2020002087 A CL 2020002087A CL 2020002087 A1 CL2020002087 A1 CL 2020002087A1
- Authority
- CL
- Chile
- Prior art keywords
- pyridin
- fluoro
- cell lymphoma
- methylsulfonimidoyl
- methoxyphenyl
- Prior art date
Links
- YZCUMZWULWOUMD-UHFFFAOYSA-N 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=CC(NC=2N=CC=C(CS(C)(=N)=O)C=2)=NC=C1F YZCUMZWULWOUMD-UHFFFAOYSA-N 0.000 title abstract 3
- 206010025323 Lymphomas Diseases 0.000 title 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 3
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 1
- 108091012583 BCL2 Proteins 0.000 abstract 1
- 101150017888 Bcl2 gene Proteins 0.000 abstract 1
- 101150039798 MYC gene Proteins 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001280 germinal center Anatomy 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al uso de 5-Fluoro-4-(4-fluoro-2-metoxifenil)-N-{4-[(S-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina (compuesto A), más específicamente (+)5-Fluoro-4-(4-fluoro-2-metoxifenil)-N-{4-[(S-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina (compuesto A´), para el tratamiento del linfoma difuso de células grandes B (LDCGB), especialmente en el tipo de células B del centro germinal del linfoma difuso de células grandes B y especialmente en el linfoma difuso de células grandes B cuyas células tienen una amplificación o translocación del gen MYC y/o del gen BCL2 y/o una sobreexpresión de MYC y/o BCL2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156576 | 2018-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002087A1 true CL2020002087A1 (es) | 2020-12-11 |
Family
ID=61223765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002087A CL2020002087A1 (es) | 2018-02-13 | 2020-08-12 | Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11701347B2 (es) |
| EP (1) | EP3752487A1 (es) |
| JP (1) | JP7280286B2 (es) |
| KR (1) | KR102764122B1 (es) |
| CN (1) | CN111727183B (es) |
| AU (1) | AU2019221019B2 (es) |
| BR (1) | BR112020016389A2 (es) |
| CA (1) | CA3090843A1 (es) |
| CL (1) | CL2020002087A1 (es) |
| EA (1) | EA202091894A1 (es) |
| IL (1) | IL276437B2 (es) |
| JO (1) | JOP20200196A1 (es) |
| MA (1) | MA51820A (es) |
| MX (1) | MX2020008447A (es) |
| SG (1) | SG11202006470RA (es) |
| WO (1) | WO2019158517A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| US11701347B2 (en) | 2018-02-13 | 2023-07-18 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
| MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| SI2256108T1 (sl) | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| CA2515132C (en) | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US7465805B2 (en) | 2004-10-05 | 2008-12-16 | Syngenta Limited | Isoxazoline derivatives and their use as herbicides |
| US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| DE102005062742A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| JP4305477B2 (ja) | 2006-07-25 | 2009-07-29 | トヨタ自動車株式会社 | 火花点火式内燃機関 |
| DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
| DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| EP2094681A1 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| JP5379787B2 (ja) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| KR20120049940A (ko) | 2009-09-04 | 2012-05-17 | 노파르티스 아게 | 키나제 억제제로서의 헤테로아릴 화합물 |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| KR20120114224A (ko) | 2009-10-12 | 2012-10-16 | 마이렉시스 인코포레이티드 | Ikk 엡실론 및/또는 tbk1의 억제제로서의 아미노-피리미딘 화합물 |
| CA2789200C (en) | 2010-03-22 | 2020-05-26 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| CA2816679A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
| WO2012101062A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101065A2 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyrimidine biaryl amine compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| JP5947818B2 (ja) | 2011-03-02 | 2016-07-06 | リード ディスカバリー センター ゲーエムベーハー | 薬学的活性化二置換ピリジン誘導体 |
| WO2012117048A1 (en) | 2011-03-02 | 2012-09-07 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| KR20140048873A (ko) | 2011-04-12 | 2014-04-24 | 알츠하이머즈 인스티튜트 오브 아메리카, 인크. | Ikk-관련 키나제 엡실론 및 tank 결합 키나제 1 억제제의 조성물 및 치료학적 용도 |
| CN102731413A (zh) | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | 一种脲类化合物、其制备方法、其中间体及其应用 |
| AU2012244745A1 (en) | 2011-04-19 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
| EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| CN103930399B (zh) | 2011-09-16 | 2016-03-16 | 拜耳知识产权有限责任公司 | 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物 |
| CN103917527B (zh) | 2011-09-16 | 2017-05-31 | 拜耳知识产权有限责任公司 | 二取代的5‑氟‑嘧啶 |
| CN105102434A (zh) | 2012-10-18 | 2015-11-25 | 拜耳药业股份公司 | 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺 |
| WO2014076028A1 (en) | 2012-11-15 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
| ME02880B (me) * | 2012-11-15 | 2018-04-20 | Bayer Pharma AG | Derivati 5-fluoro- n- (piridin -2-il}piridi n- 2 - amina koji sadrze sulfoksiminsku grupu |
| EP3016945B1 (en) | 2013-07-04 | 2017-05-03 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
| US9856242B2 (en) | 2014-03-13 | 2018-01-02 | Bayer Pharma Aktiengesellscaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
| JP2018509440A (ja) * | 2015-03-24 | 2018-04-05 | バイエル ファーマ アクチエンゲゼルシャフト | リンパ腫の治療のための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用 |
| US11701347B2 (en) | 2018-02-13 | 2023-07-18 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma |
-
2019
- 2019-02-12 US US16/969,460 patent/US11701347B2/en active Active
- 2019-02-12 BR BR112020016389-9A patent/BR112020016389A2/pt not_active Application Discontinuation
- 2019-02-12 JP JP2020565543A patent/JP7280286B2/ja active Active
- 2019-02-12 WO PCT/EP2019/053407 patent/WO2019158517A1/en not_active Ceased
- 2019-02-12 IL IL276437A patent/IL276437B2/en unknown
- 2019-02-12 CN CN201980013294.2A patent/CN111727183B/zh active Active
- 2019-02-12 AU AU2019221019A patent/AU2019221019B2/en active Active
- 2019-02-12 EP EP19704618.8A patent/EP3752487A1/en active Pending
- 2019-02-12 JO JOP/2020/0196A patent/JOP20200196A1/ar unknown
- 2019-02-12 MA MA051820A patent/MA51820A/fr unknown
- 2019-02-12 SG SG11202006470RA patent/SG11202006470RA/en unknown
- 2019-02-12 MX MX2020008447A patent/MX2020008447A/es unknown
- 2019-02-12 KR KR1020207022928A patent/KR102764122B1/ko active Active
- 2019-02-12 EA EA202091894A patent/EA202091894A1/ru unknown
- 2019-02-12 CA CA3090843A patent/CA3090843A1/en active Pending
-
2020
- 2020-08-12 CL CL2020002087A patent/CL2020002087A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20200196A1 (ar) | 2020-08-13 |
| KR102764122B1 (ko) | 2025-02-05 |
| EA202091894A1 (ru) | 2020-12-28 |
| US20210015806A1 (en) | 2021-01-21 |
| AU2019221019B2 (en) | 2024-05-02 |
| BR112020016389A2 (pt) | 2020-12-15 |
| IL276437B2 (en) | 2024-03-01 |
| US11701347B2 (en) | 2023-07-18 |
| JP2021514386A (ja) | 2021-06-10 |
| MX2020008447A (es) | 2020-09-28 |
| CA3090843A1 (en) | 2019-08-22 |
| IL276437A (en) | 2020-09-30 |
| JP7280286B2 (ja) | 2023-05-23 |
| SG11202006470RA (en) | 2020-08-28 |
| WO2019158517A1 (en) | 2019-08-22 |
| KR20200119800A (ko) | 2020-10-20 |
| MA51820A (fr) | 2021-05-19 |
| IL276437B1 (en) | 2023-11-01 |
| AU2019221019A1 (en) | 2020-07-23 |
| CN111727183A (zh) | 2020-09-29 |
| EP3752487A1 (en) | 2020-12-23 |
| CN111727183B (zh) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004541A (es) | Edicion de genes de celulas primarias. | |
| MX2022004080A (es) | Receptor de antígeno quimérico potenciado para la modificación de células efectoras inmunitarias y uso del mismo. | |
| MX2022000553A (es) | Modificación de células efectoras inmunitarias y uso de las mismas. | |
| MX2023002195A (es) | Compuestos y metodos para el tratamiento de infecciones virales. | |
| MX2020005477A (es) | Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc. | |
| MX2020012028A (es) | Metodos y composiciones para tratar el cancer. | |
| EA202191559A1 (ru) | Модифицированные аминовые липиды | |
| EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
| MX2020012295A (es) | Composiciones de fusosoma y usos de estas. | |
| SA520411636B1 (ar) | صيغ جسيمات نانوية دهنية | |
| MX2022006444A (es) | Linfocitos t activados por bite ex vivo. | |
| MX385562B (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. | |
| MX2020003954A (es) | Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa. | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| MX382337B (es) | Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias. | |
| GB2533063A (en) | Structures and methods with reduced sensitivity to surface charge | |
| MX2013014544A (es) | Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia. | |
| BR112014017840A8 (pt) | Compostos terapeuticamente ativos, sua composição farmacêutica e seu uso | |
| ECSP15018618A (es) | Inhibidores no nucleósidos de la transcriptasa inversa | |
| AR111360A1 (es) | Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas | |
| MX2012008717A (es) | Composiciones para el cuidado oral. | |
| EA201290976A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| CY1120800T1 (el) | Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων | |
| CY1123144T1 (el) | Επαγωγη καρδιακης αναγεννησης μe microrna | |
| MX2018012945A (es) | Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. |